111, Inc. and Jianming Pharmaceutical Group have entered into a strategic cooperation agreement to develop an online chronic disease management platform for the hepatobiliary disease market in China. As part of the agreement, Jianming Pharmaceutical's liver and gallbladder medications will be available on 111's network, initially leveraging its SMART supply chain services to distribute products in Fujian province, and eventually expanding to the out-of-hospital market nationwide. The chronic disease management platform aims to address the large unmet need in China's hepatobiliary disease market. Currently, there are over 90 million people suffering from hepatitis B, over 13 million people suffering from chronic hepatitis C, and over 100 million with fatty liver diseases in China. People in China are generally not very well educated about hepatobiliary diseases, and coupled with an inadequate allocation of medical resources, as well as a disconnected healthcare system, the level of diagnosis and treatment varies considerably across China, resulting in late diagnosis, high treatment costs, and poor treatment results. Using 111's advanced technological capabilities and expansive network of doctors and pharmacies, patients will have access to disease specialists that can quickly diagnose and appropriately treat their underlying disease through the online platform. Additionally, the platform will connect doctors with educational resources and discussion boards relating to the diagnosis and available treatments for diseases effecting the liver, gallbladder, and bile ducts.